Evofem Biosciences appoints Jenny Yip from Adjuvant Capital to board of directors

Evofem Biosciences, Inc.

Jenny Yip, Managing Partner at Adjuvant Capital, elected to Evofem board effective August 2, 2022.
Adjuvant Capital previously invested $25 million to fund Phase 3 EVOGUARD trial for Phexxi in chlamydia/gonorrhea prevention.
Top-line results from EVOGUARD trial expected fall 2022.
Board expands from five to six independent directors with Yip's appointment.
Yip's term expires at 2023 annual meeting; standard indemnification agreement entered.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jenny Yip

Director

EVFM · Evofem Biosciences, Inc.

Effective: 2022-08-02
Filed: August 3, 2022, 7:59 PM ET

On August 2, 2022, the Board of Directors (the “Board”) of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), elected Jenny Yip, to the Board to fill the existing vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jenny Yip was elected as Director at Evofem Biosciences, Inc..

Action: elected
Role: Director

Exact text from the filing

On August 2, 2022, the Board of Directors (the “Board”) of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), elected Jenny Yip, to the Board to fill the existing vacancy on the Board.

View on SEC.gov

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001618835-22-000142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.